Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 4/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708598 | 0.99 | AGTR2 (0.37) | AGTR2AGTR1MMP3 | |
| SCHEMBL3705183 | 0.99 | AGTR2 (0.37) | AGTR2AGTR1MMP3 | |
| SCHEMBL3705821 | 0.97 | MMP3 (0.36) | AGTR2AGTR1MMP3 | |
| SCHEMBL3716506 | 0.92 | MMP3 (0.36) | AGTR2AGTR1MMP3 | |
| SCHEMBL3711883 | 0.91 | SCN9A (0.36) | — | |
| SCHEMBL3704206 | 0.90 | SCN9A (0.36) | AGTR2 | |
| SCHEMBL3710733 | 0.90 | SCN9A (0.37) | — | |
| SCHEMBL3710484 | 0.90 | AGTR1 (0.40) | AGTR2AGTR1 | |
| SCHEMBL3708320 | 0.90 | AGTR2 (0.41) | AGTR2AGTR1 | |
| SCHEMBL3706651 | 0.89 | AGTR1 (0.41) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2471782-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Kowa Company, Ltd. (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122906-A1 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AGTR2, AGTR1, PPARA | AGTR2 1/4885AGTR1 2/4885MMP3 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.